— Experienced Leader Brings Extensive Record of Global Strategic and Commercial Operational Accomplishments and Successful Product Launches — BRISBANE, Calif. --(BUSINESS WIRE)--Jun. 11, 2018-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for
— European APPEAL ( A llergy to P eanuts Im p acting E motions a nd L ife) Study Finds Peanut Allergy Has a Daily Impact on More than 80% of People with Peanut Allergy and Parents or Caregivers of Peanut-Allergic Minors — — Data Discussed at EAACI 2018 Reveal Uncertainty, Bullying and High Levels
— In U.S. Survey , Allergists Want Consensus in Oral Immunotherapy Terminology — — U.S. Allergists Preferred “Tolerated Dose” as the Most Clinically Relevant Term to Communicate Desensitization Levels to Oral Immunotherapy Patients — BRISBANE, Calif. & MUNICH, Germany --(BUSINESS WIRE)--May 29,
New analyses including adults enrolled in the Phase 3 PALISADE trial of AR101 show efficacy across the entire intent-to-treat population of peanut-allergic patients ages 4-55 New immunologic subset analyses show that AR101 treatment was linked to depletion of peanut-specific TH2A cells believed to
— Late-Breaking Oral Presentations on AR101 Phase 3 PALISADE Results in Peanut-Allergic Children and Adults and on European Study of Psychosocial Impact of Peanut Allergy — BRISBANE, Calif. --(BUSINESS WIRE)--May 15, 2018-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company
BRISBANE, Calif. --(BUSINESS WIRE)--May 9, 2018-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that members of the Aimmune executive management team will participate in four upcoming investor
BRISBANE, Calif. --(BUSINESS WIRE)--May 8, 2018-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced financial results for the first quarter 2018. As of March 31, 2018 , cash, cash equivalents and
Company began 2018 with approximately $182 Million in cash and investments Pro-forma year-end 2017 cash and investments of approximately $372 Million , including net proceeds from the recently completed public offering Announced over-enrollment in the ARTEMIS Phase 3 trial Additional AR101 clinical
BRISBANE, Calif. --(BUSINESS WIRE)--Mar. 7, 2018-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that members of the Aimmune executive management team will participate in four upcoming investor
— Late-Breaking Oral Presentation by Dr. Stacie Jones — — PALISADE Results Expected to Provide Core Element of BLA Submission by Year-End 2018 — BRISBANE, Calif. & ORLANDO, Fla. --(BUSINESS WIRE)--Mar. 4, 2018-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing
